Foghorn Therapeutics reduces ATM program capacity from $200M to $100M

Foghorn Therapeutics Inc.

Amendment No. 1 to Sales Agreement with TD Cowen lowers maximum shares to be sold from $200M to $100M.
Other terms of the at-the-market offering program remain unchanged; no new public offering announced.
Amendment effective March 20, 2025; shares sold pursuant to previously effective shelf registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.